Impact of basal-like breast carcinoma determination for a more specific therapy - PubMed (original) (raw)
Review
doi: 10.1159/000123847. Epub 2008 Jun 10.
Affiliations
- PMID: 18544964
- DOI: 10.1159/000123847
Review
Impact of basal-like breast carcinoma determination for a more specific therapy
Emad A Rakha et al. Pathobiology. 2008.
Abstract
Recent advances in high-throughput molecular technologies have made it possible to begin to tackle the molecular complexity of breast cancer and have contributed to the realisation that this biologic heterogeneity has implications for treatment. One of the major achievements of class discovery studies in breast cancer is the identification of a basal-like subtype that is characterised by absence of expression of hormone receptors and HER2 and has molecular features in common with basal/myoepithelial cells of the breast. Basal-like cancers have attracted attention as a poor prognostic class of tumours that lack the benefit of currently available targeted therapy. However, basal-like cancer as a distinct class of tumours, which share a specific molecular profile, are characterised by high proliferative activity and express specific markers, is a good candidate for development of specific targeted therapy. It is likely that in the near future, the ongoing research studies and clinical trials will provide an evidence-based approach to the best treatment strategy that can be applied to these tumours. In this review, we discuss the main features of basal-like tumours and recent evidence on the different available therapeutic approaches.
Copyright 2008 S. Karger AG, Basel.
Similar articles
- Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice.
Diaz LK, Cryns VL, Symmans WF, Sneige N. Diaz LK, et al. Adv Anat Pathol. 2007 Nov;14(6):419-30. doi: 10.1097/PAP.0b013e3181594733. Adv Anat Pathol. 2007. PMID: 18049131 Review. - Characterization of breast cancer subtypes by quantitative assessment of biological parameters: relationship with clinicopathological characteristics, biological features and prognosis.
Del Casar JM, Martín A, García C, Corte MD, Alvarez A, Junquera S, González LO, Bongera M, García-Muñiz JL, Allende MT, Vizoso F. Del Casar JM, et al. Eur J Obstet Gynecol Reprod Biol. 2008 Dec;141(2):147-52. doi: 10.1016/j.ejogrb.2008.07.021. Epub 2008 Sep 2. Eur J Obstet Gynecol Reprod Biol. 2008. PMID: 18768247 - Morphological characteristics of basal-like subtype of breast carcinoma with special reference to cytopathological features.
Ishihara A, Tsuda H, Kitagawa K, Yoneda M, Shiraishi T. Ishihara A, et al. Breast Cancer. 2009;16(3):179-85. doi: 10.1007/s12282-009-0108-x. Epub 2009 May 23. Breast Cancer. 2009. PMID: 19466513 - EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy.
Milanezi F, Carvalho S, Schmitt FC. Milanezi F, et al. Expert Rev Mol Diagn. 2008 Jul;8(4):417-34. doi: 10.1586/14737159.8.4.417. Expert Rev Mol Diagn. 2008. PMID: 18598224 Review. - What is triple-negative breast cancer?
Irvin WJ Jr, Carey LA. Irvin WJ Jr, et al. Eur J Cancer. 2008 Dec;44(18):2799-805. doi: 10.1016/j.ejca.2008.09.034. Epub 2008 Nov 12. Eur J Cancer. 2008. PMID: 19008097 Review.
Cited by
- Assessment of basal-like breast cancer by circulating tumor DNA analysis.
Wei W, Zhang X, Sun S, Xia B, Liang X, Cui Y, Gao S, Pang D. Wei W, et al. Oncol Lett. 2018 May;15(5):7389-7396. doi: 10.3892/ol.2018.8224. Epub 2018 Mar 9. Oncol Lett. 2018. PMID: 29725452 Free PMC article. - The changing role of pathology in breast cancer diagnosis and treatment.
Leong AS, Zhuang Z. Leong AS, et al. Pathobiology. 2011;78(2):99-114. doi: 10.1159/000292644. Epub 2011 Jun 14. Pathobiology. 2011. PMID: 21677473 Free PMC article. Review. - Basal-like breast cancer: molecular profiles, clinical features and survival outcomes.
Milioli HH, Tishchenko I, Riveros C, Berretta R, Moscato P. Milioli HH, et al. BMC Med Genomics. 2017 Mar 28;10(1):19. doi: 10.1186/s12920-017-0250-9. BMC Med Genomics. 2017. PMID: 28351365 Free PMC article. - Securin promotes the identification of favourable outcome in invasive breast cancer.
Talvinen K, Karra H, Hurme S, Nykänen M, Nieminen A, Anttinen J, Kuopio T, Kronqvist P. Talvinen K, et al. Br J Cancer. 2009 Sep 15;101(6):1005-10. doi: 10.1038/sj.bjc.6605237. Epub 2009 Aug 18. Br J Cancer. 2009. PMID: 19690544 Free PMC article. - Correlation of Forkhead Box c2 with subtypes and invasive ability of invasive breast cancer.
Dai J, Wang JY, Yang LL, Xiao Y, Qu ZL, Qin SH, Ruan QR. Dai J, et al. J Huazhong Univ Sci Technolog Med Sci. 2014 Dec;34(6):896-901. doi: 10.1007/s11596-014-1370-5. Epub 2014 Dec 6. J Huazhong Univ Sci Technolog Med Sci. 2014. PMID: 25480587
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous